Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer

Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas Böhle, Joan Palou, J. Alfred Witjes, Hideyuki Akaza, Roger Buckley, Maurizio Brausi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Context: Although the European Association of Urology (EAU), First International Consultation on Bladder Tumors (FICBT), National Comprehensive Cancer Network (NCCN), and American Urological Association (AUA) guidelines all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC), the four guidelines vary with respect to important issues such as the definitions of risk levels and the appropriate management strategies for patients in these risk categories. Objective: To build on the existing framework provided by the EAU, FICBT, NCCN, and AUA guidelines and to provide consensus on the definitions of low-, intermediate-, and high-risk NMIBC as well as practical recommendations for the management of patients in each of these risk categories. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the treatment and management of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the EAU, FICBT, NCCN, and AUA. Evidence synthesis: On the basis of a review of the current literature and the EAU, FICBT, NCCN, and AUA guidelines, the IBCG developed a user-friendly treatment algorithm and practical recommendations for the management of patients with low-, intermediate-, and high-risk NMIBC. Conclusions: A complete transurethral resection of the bladder tumour (TURBT) plus an immediate, postoperative chemotherapeutic instillation is recommended for all patients with NMIBC except those with obvious or suspected bladder wall perforation. For intermediate-risk disease, intravesical induction bacillus Calmette-Guérin (BCG) plus maintenance or intravesical chemotherapy are recommended; for high-risk disease, BCG induction plus maintenance is the recommended management strategy. The appropriate management of recurrences depends on the patient's level of risk, whereas the management of treatment failures depends on both the type of failure and the patient's level of risk for recurrence and disease progression.

Original languageEnglish
Pages (from-to)651-666
Number of pages16
JournalEuropean Urology, Supplements
Volume7
Issue number10
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Practice Management
Urinary Bladder Neoplasms
Guidelines
Urology
Referral and Consultation
Bacillus
Neoplasms
Maintenance
Recurrence
Risk Management
Treatment Failure
Practice Guidelines
Disease Progression
Consensus
Urinary Bladder
Language

Keywords

  • Bacillus Calmette-Guérin
  • Follow-up of non-muscle invasive bladder cancer
  • Intravesical chemotherapy
  • Management of non-muscle invasive bladder cancer
  • Management of recurrences
  • Management of treatment failures
  • Post-operative chemotherapeutic instillation
  • Recommendations
  • Transurethral resection of the bladder tumour

ASJC Scopus subject areas

  • Urology

Cite this

Lamm, D., Colombel, M., Persad, R., Soloway, M., Böhle, A., Palou, J., ... Brausi, M. (2008). Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer. European Urology, Supplements, 7(10), 651-666. https://doi.org/10.1016/j.eursup.2008.07.009

Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer. / Lamm, Donald; Colombel, Marc; Persad, Raj; Soloway, Mark; Böhle, Andreas; Palou, Joan; Witjes, J. Alfred; Akaza, Hideyuki; Buckley, Roger; Brausi, Maurizio.

In: European Urology, Supplements, Vol. 7, No. 10, 01.10.2008, p. 651-666.

Research output: Contribution to journalArticle

Lamm, D, Colombel, M, Persad, R, Soloway, M, Böhle, A, Palou, J, Witjes, JA, Akaza, H, Buckley, R & Brausi, M 2008, 'Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer', European Urology, Supplements, vol. 7, no. 10, pp. 651-666. https://doi.org/10.1016/j.eursup.2008.07.009
Lamm, Donald ; Colombel, Marc ; Persad, Raj ; Soloway, Mark ; Böhle, Andreas ; Palou, Joan ; Witjes, J. Alfred ; Akaza, Hideyuki ; Buckley, Roger ; Brausi, Maurizio. / Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer. In: European Urology, Supplements. 2008 ; Vol. 7, No. 10. pp. 651-666.
@article{97f8892b14cb46d1bcaf1f2fdbea27dd,
title = "Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer",
abstract = "Context: Although the European Association of Urology (EAU), First International Consultation on Bladder Tumors (FICBT), National Comprehensive Cancer Network (NCCN), and American Urological Association (AUA) guidelines all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC), the four guidelines vary with respect to important issues such as the definitions of risk levels and the appropriate management strategies for patients in these risk categories. Objective: To build on the existing framework provided by the EAU, FICBT, NCCN, and AUA guidelines and to provide consensus on the definitions of low-, intermediate-, and high-risk NMIBC as well as practical recommendations for the management of patients in each of these risk categories. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the treatment and management of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the EAU, FICBT, NCCN, and AUA. Evidence synthesis: On the basis of a review of the current literature and the EAU, FICBT, NCCN, and AUA guidelines, the IBCG developed a user-friendly treatment algorithm and practical recommendations for the management of patients with low-, intermediate-, and high-risk NMIBC. Conclusions: A complete transurethral resection of the bladder tumour (TURBT) plus an immediate, postoperative chemotherapeutic instillation is recommended for all patients with NMIBC except those with obvious or suspected bladder wall perforation. For intermediate-risk disease, intravesical induction bacillus Calmette-Gu{\'e}rin (BCG) plus maintenance or intravesical chemotherapy are recommended; for high-risk disease, BCG induction plus maintenance is the recommended management strategy. The appropriate management of recurrences depends on the patient's level of risk, whereas the management of treatment failures depends on both the type of failure and the patient's level of risk for recurrence and disease progression.",
keywords = "Bacillus Calmette-Gu{\'e}rin, Follow-up of non-muscle invasive bladder cancer, Intravesical chemotherapy, Management of non-muscle invasive bladder cancer, Management of recurrences, Management of treatment failures, Post-operative chemotherapeutic instillation, Recommendations, Transurethral resection of the bladder tumour",
author = "Donald Lamm and Marc Colombel and Raj Persad and Mark Soloway and Andreas B{\"o}hle and Joan Palou and Witjes, {J. Alfred} and Hideyuki Akaza and Roger Buckley and Maurizio Brausi",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.eursup.2008.07.009",
language = "English",
volume = "7",
pages = "651--666",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer

AU - Lamm, Donald

AU - Colombel, Marc

AU - Persad, Raj

AU - Soloway, Mark

AU - Böhle, Andreas

AU - Palou, Joan

AU - Witjes, J. Alfred

AU - Akaza, Hideyuki

AU - Buckley, Roger

AU - Brausi, Maurizio

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Context: Although the European Association of Urology (EAU), First International Consultation on Bladder Tumors (FICBT), National Comprehensive Cancer Network (NCCN), and American Urological Association (AUA) guidelines all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC), the four guidelines vary with respect to important issues such as the definitions of risk levels and the appropriate management strategies for patients in these risk categories. Objective: To build on the existing framework provided by the EAU, FICBT, NCCN, and AUA guidelines and to provide consensus on the definitions of low-, intermediate-, and high-risk NMIBC as well as practical recommendations for the management of patients in each of these risk categories. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the treatment and management of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the EAU, FICBT, NCCN, and AUA. Evidence synthesis: On the basis of a review of the current literature and the EAU, FICBT, NCCN, and AUA guidelines, the IBCG developed a user-friendly treatment algorithm and practical recommendations for the management of patients with low-, intermediate-, and high-risk NMIBC. Conclusions: A complete transurethral resection of the bladder tumour (TURBT) plus an immediate, postoperative chemotherapeutic instillation is recommended for all patients with NMIBC except those with obvious or suspected bladder wall perforation. For intermediate-risk disease, intravesical induction bacillus Calmette-Guérin (BCG) plus maintenance or intravesical chemotherapy are recommended; for high-risk disease, BCG induction plus maintenance is the recommended management strategy. The appropriate management of recurrences depends on the patient's level of risk, whereas the management of treatment failures depends on both the type of failure and the patient's level of risk for recurrence and disease progression.

AB - Context: Although the European Association of Urology (EAU), First International Consultation on Bladder Tumors (FICBT), National Comprehensive Cancer Network (NCCN), and American Urological Association (AUA) guidelines all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC), the four guidelines vary with respect to important issues such as the definitions of risk levels and the appropriate management strategies for patients in these risk categories. Objective: To build on the existing framework provided by the EAU, FICBT, NCCN, and AUA guidelines and to provide consensus on the definitions of low-, intermediate-, and high-risk NMIBC as well as practical recommendations for the management of patients in each of these risk categories. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to the treatment and management of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the EAU, FICBT, NCCN, and AUA. Evidence synthesis: On the basis of a review of the current literature and the EAU, FICBT, NCCN, and AUA guidelines, the IBCG developed a user-friendly treatment algorithm and practical recommendations for the management of patients with low-, intermediate-, and high-risk NMIBC. Conclusions: A complete transurethral resection of the bladder tumour (TURBT) plus an immediate, postoperative chemotherapeutic instillation is recommended for all patients with NMIBC except those with obvious or suspected bladder wall perforation. For intermediate-risk disease, intravesical induction bacillus Calmette-Guérin (BCG) plus maintenance or intravesical chemotherapy are recommended; for high-risk disease, BCG induction plus maintenance is the recommended management strategy. The appropriate management of recurrences depends on the patient's level of risk, whereas the management of treatment failures depends on both the type of failure and the patient's level of risk for recurrence and disease progression.

KW - Bacillus Calmette-Guérin

KW - Follow-up of non-muscle invasive bladder cancer

KW - Intravesical chemotherapy

KW - Management of non-muscle invasive bladder cancer

KW - Management of recurrences

KW - Management of treatment failures

KW - Post-operative chemotherapeutic instillation

KW - Recommendations

KW - Transurethral resection of the bladder tumour

UR - http://www.scopus.com/inward/record.url?scp=51549088346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549088346&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2008.07.009

DO - 10.1016/j.eursup.2008.07.009

M3 - Article

AN - SCOPUS:51549088346

VL - 7

SP - 651

EP - 666

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 10

ER -